International
The Morning Science

What science found today

‹
 

Research

A scFv-based immunotoxin for selective targeting and cytotoxicity against c-Met-overexpressing cancer cells: an integrated in silico and in vitro study

Nature ·

The Brief

  • The study describes a scFv-based immunotoxin designed to selectively target cancer cells that overexpress c-Met.
  • The work is reported as an integrated in silico and in vitro study, so its evidence comes from computational modelling and laboratory cell experiments.
  • The source summary is not available, so the reported cytotoxicity results cannot be detailed here.

Why it matters

It is an early-stage preclinical study of a targeted therapy approach against c-Met-overexpressing tumours, which science readers can use to track progress in immunotoxin design.

Who’s affected

  • cancer researchers
  • biomedical scientists working on targeted therapies

How do you feel about this?

0 Comments

    A scFv-based immunotoxin for selective targeting and cytotoxicity against c-Met-overexpressing cancer cells: an integrated in silico and in vitro study – The Morning Science